Highlighted Articles: Highlighted article – May 2014

T cell-specific BLIMP-1 deficiency exacerbates experimental autoimmune encephalomyelitis in nonobese diabetic mice by increasing Th1 and Th17 cells

Ming-Hong Lin, Li-Tzu Yeh, Shyi-Jou Chen, Hsin-Ying C. Chiou, Chin-Chen Chu, Linju B. Yen, Kuo-I Lin, Deh-Ming Chang, Huey-Kang Sytwu

Clinical Immunology, Volume 151, Issue 2, April 2014, Pages 101–113

Full article on Science Direct – free access until 9 October 2014

Chin-Chen Chu

Chin-Chen Chu, MD, PhD, is Associate Professor and Head of the Division of Obstetric-Gynecologic and Pediatric Anesthesia, at the Chi Mei Medical Center, Tainan, Taiwan. He is a clinical Anesthesiologist with two main interests in (1) the development of novel local anesthetics and (2) the effect of anesthetic drugs on developing brain. Besides, in cooperation with Professor Huey-Kang Sytwu, he also takes part in the research of the role of Th1 and Th17 cells in autoimmune diabetes and the therapy of type I diabetes.

Huey-Kang Sytwu

Huey-Kang Sytwu, MD, PhD, is Professor of Immunology in the Department of Microbiology and Immunology and President of the National Defense Medical Center, Taipei, Taiwan. He holds MD degree from the National Defense Medical Center and PhD degree from the Stanford University School of Medicine, USA. Dr. Sytwu’s laboratory has successfully generated more than 20 genetically modified non-obese diabetic (NOD) lines, including Th1 and Th2 double transgenic, insulin promoter-driven decoy receptor 3 (DcR3), programmed death ligand 1 (PD-L1) and PD-L2, single-chain anti-4-1BB Fv and anti-CTLA4 Fv, heme oxygenase 1 (HO-1), chemokine receptor D6 mice, lck promoter-driven B lymphocyte induced maturation protein 1 (Blimp-1), PEST-domain enriched tyrosine phosphatase (Pep), 1,6 N-acetylglucosaminyltransferase V (Mgat5), β3Gn transferase 2 (T2), c-Maf, SUMO-defective c-Maf, Cre transgenic NOD mice, and some cytokine knockout/knockdown NOD mice including IL-12 knockout, IL-23, IL-27 and IL-21 knockdown mice for the study of autoimmune diabetes, both on the dissection of its immunopathogenic mechanisms and on the development of novel therapeutic approaches.

This content is also available in: Español Português

Scroll to Top